The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.
Aprea Therapeutics, the US-based cancer treatment spinout of Karolinska Institute, yesterday increased its initial public offering to nearly $97.8m after underwriters took up the over-allotment option in full.
The company had issued 5.7 million shares priced at $15 each last week, raising $85m and seeing shares rise more than a third to close at $20.50 on the first day of trading.
Shares closed at $18.94 yesterday, but having consistently traded above the IPO price, joint-booking running managers…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
